Abstract
19 patients with locally advanced or cutaneous metastatic breast cancer were treated with the topical vitamin D analogue calcipotriol 100 micrograms daily. 14 patients completed 6 weeks' treatment; 3 showed a 50% reduction in the bidimensional diameter of treated lesions and 1 other patient showed a minimal response. 2 patients became hypercalcaemic during treatment. In all patients who responded the tumours contained receptors for 1,25-dihydroxyvitamin D3, shown by immunocytochemistry.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Topical
-
Adult
-
Aged
-
Aged, 80 and over
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / pathology
-
Calcitriol / administration & dosage
-
Calcitriol / adverse effects
-
Calcitriol / analogs & derivatives*
-
Calcitriol / therapeutic use
-
Carcinoma / drug therapy*
-
Carcinoma / secondary
-
Drug Administration Schedule
-
Drug Evaluation
-
Female
-
Humans
-
Hypercalcemia / chemically induced
-
Middle Aged
-
Receptors, Calcitriol
-
Receptors, Estrogen / drug effects
-
Receptors, Steroid / drug effects
-
Skin Neoplasms / drug therapy*
-
Skin Neoplasms / secondary
Substances
-
Receptors, Calcitriol
-
Receptors, Estrogen
-
Receptors, Steroid
-
calcipotriene
-
Calcitriol